Targets › CFD
2 programs from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Hematology, Cardiovascular; next expected readout May 2027.
Serine protease that initiates the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. In contrast to other complement pathways (classical, lectin and GZMK) that are directly activated by pathogens or antigen-antibody complexes, the alternative complement pathway is initiated by the…. (UniProt, P00746)
Open in Phaseline: the race on CFD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Danicopan Complement factor D inhibitor | CFD | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | May 2027 |
| AstraZeneca | ALXN2220 Factor D complement inhibitor | CFD | Phase 2 | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Feb 2029 |
Paroxysmal Nocturnal Hemoglobinuria (2) Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.